Pulmatrix wins FDA nod for PhII trial of inhaled anti-fungal therapy

Pulmatrix (NSDQ:PULM) said today that the FDA approved a Phase II trial of the company’s inhaled formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in people with asthma.
The Lexington, Mass.-based company plans to kick off the trial in the first half of 2019, with top-line data expected in the second quarter of 2020.
Get the full story at our sister site, Drug Delivery Business News.
The post Pulmatrix wins FDA nod for PhII trial of inhaled anti-fungal therapy appeared first on MassDevice.

Source: Mass Device - February 7, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Featured Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news